key: cord-0428173-19v57r6v
authors: Liu, Y.; Teo, S. M.; Meric, G.; Tang, H. H.; Zhu, Q.; Sanders, J. G.; Vazquez-Baeza, Y.; Verspoor, K.; Vartiainen, V. A.; Jousilahti, P.; Lahti, L.; Niiranen, T.; Havulinna, A. S.; Knight, R.; Salomaa, V.; Inouye, M.
title: The gut microbiome is a significant risk factor for future chronic lung disease
date: 2022-03-23
journal: nan
DOI: 10.1101/2022.03.22.22272736
sha: a1407245418139144ec0623a18f686c16e163905
doc_id: 428173
cord_uid: 19v57r6v

Background: The gut-lung axis is generally recognized, but there are few large studies of the gut microbiome and incident respiratory disease in adults. Objectives: To investigate the associations between gut microbiome and respiratory disease and to construct predictive models from baseline gut microbiome profiles for incident asthma or chronic obstructive pulmonary disease (COPD). Methods: Shallow metagenomic sequencing was performed for stool samples from a prospective, population-based cohort (FINRISK02; N=7,115 adults) with linked national administrative health register derived classifications for incident asthma and COPD up to 15 years after baseline. Generalised linear models and Cox regressions were utilised to assess associations of microbial taxa and diversity with disease occurrence. Predictive models were constructed using machine learning with extreme gradient boosting. Models considered taxa abundances individually and in combination with other risk factors, including sex, age, body mass index and smoking status. Results: A total of 695 and 392 significant microbial associations at different taxonomic levels were found with incident asthma and COPD, respectively. Gradient boosting decision trees of baseline gut microbiome predicted incident asthma and COPD with mean area under the curves of 0.608 and 0.780, respectively. For both incident asthma and COPD, the baseline gut microbiome had C-indices of 0.623 for asthma and 0.817 for COPD, which were more predictive than other conventional risk factors. The integration of gut microbiome and conventional risk factors further improved prediction capacities. Subgroup analyses indicated gut microbiome was significantly associated with incident COPD in both current smokers and non-smokers, as well as in individuals who reported never smoking. Conclusions: The gut microbiome is a significant risk factor for incident asthma and incident COPD and is largely independent of conventional risk factors.

Asthma and chronic obstructive pulmonary disease (COPD) represent the vast majority of 77 chronic respiratory diseases worldwide, causing a considerable burden on health and 78 economy [1, 2] . Both asthma and COPD are recognized as heterogeneous diseases with 79 diverse phenotypes and various underlying mechanisms [3] [4] [5] [6] . Currently, spirometry-confirmed 80 airflow limitation is the most common reference standard for establishing diagnoses of asthma 81

and COPD, yet a negative spirometry test result does not rule out the disease [7, 8] . Other 82 criteria that complement evaluation include self-reported symptoms, medical history, physical 83 examination and other diagnoses such as infection, interstitial lung disease, and others [7, 9] . 84

Despite rapidly changing assessments and treatments, both asthma and COPD remain largely 85 underdiagnosed and thus undertreated, leading to lesser quality of life and poorer disease 86

outcomes [3, 9] . 87

With recent advances in high-throughput sequencing, improved characterisation of the human 88 respiratory and gastrointestinal microbiome has been followed by growing recognition of the 89 link between human microbiota and chronic respiratory disease [10, 11] . The gut microbiome 90

is by far the largest and most studied microbial community in the human body [11, 12] . 91

Although the lung microbiome has become well characterized only recently, the link between 92 the lung microbiome and respiratory diseases has been generally acknowledged [10, [13] [14] [15] .

"Dysbiotic" changes in both airway and gut microbiome have been linked to respiratory 94 diseases; however, the precise mechanism or causal pathway is, as yet, not well 95 understood [16] [17] [18] [19] . Emerging evidence suggests cross-talk between gut microbiome and the 96 lungs, via changes to immune responses as well as an interaction of microbiota between the 97 sites, in a hypothesised "gut-lung axis" [11, 20] . 98

Existing studies on the association between gut microbiota and asthma have focused mainly 99 on disease development during childhood [21] [22] [23] which is driven by evidence of the influence 100 of early-life microbial exposures on immune function [24, 25] . Previous cross-sectional studies 101

have reported compositional and functional differences of the gut microbiome between adult 102 asthma patients and healthy controls [26] [27] [28] [29] . However, little is known about whether and to 103 what extent the gut microbiome affects prospective risk of developing incident asthma in 104

adults. For COPD, there have been far fewer studies on the link between the gut microbiome 105 and disease. Recently, the first analysis of gut microbiome in COPD by Bowerman et al. 106 reported that the faecal microbiome and metabolome significantly differentiate COPD patients 107 and healthy controls [30] , which suggests a possible avenue for further investigation using 108 prospective population-scale datasets. Finally, it is only in recent years that methodological 109 and technological advances have opened up the possibility of using large-scale microbial data 110

to predict human respiratory disease [22, 31] , but the feasibility of such measures has yet to 111 be evaluated for COPD. 112

Here we report association analysis and predictive modelling of the gut microbiome and 113 incident asthma and COPD using stool samples from >7,000 participants of a prospective 114 population-based cohort (FINRISK 2002) with electronic health records (EHRs) over ~15 115

years of follow-up [32] . Specifically, we (1) describe the gut microbial composition from shallow 116 shotgun metagenomic sequencing and assess the associations with incident asthma and 117 COPD, (2) employ machine learning approaches to quantify the predictive capacities of the 118 gut microbiome at baseline for incident respiratory disease, and (3) construct integrated 119 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 models of the gut microbiome and conventional risk factors and evaluated their predictive 120

performance. 121

A total of 7,115 FINRISK02 participants with baseline gut microbiome profiles and EHR 123 linkage were available for the present study. A summary description of the cohort is given in 124

the Methods and baseline characteristics are reported in Table 1 . After quality control and 125 exclusion criteria were applied, 435 and 145 incident cases of asthma and COPD, 126

respectively, occurred during a median follow-up of 14.8 years after gut microbiome sampling 127 at baseline. Notably, more males than females developed COPD, and incident COPD cases 128 displayed older baseline age than non-cases (P<0.001). The age of onset of incident COPD 129 was significantly older compared to incident asthma (P<0.001). A higher body mass index 130

(BMI) was observed in asthma cases vs non-cases (P=0.002), while there was no significant 131 difference in BMI between COPD cases and non-cases. For both COPD and asthma, a higher 132

proportion of current smokers during the survey year were observed in disease cases than 133 non-cases. 134

Individual gut microbiome compositions were characterized by shallow shotgun metagenomic 136 sequencing of stool samples (Methods). The present study focused on microbial taxa whose 137 relative abundance exceeded 0.01% in at least 1% of samples; this yielded 46 phyla, 71 138 classes, 124 orders, 232 families, 617 genera and 1,224 species, as classified according to 139

the Genome Taxonomy Database (GTDB) release 89 [33] . The majority of the gut microbiota 140

were dominated by the Firmicutes_A and Bacteroidota phyla (Fig 1A) , which mostly 141 comprised members of classes Clostridia and Bacteroidia, respectively. At the genus level, 142

Faecalibacterium and Agathobacter in phylum Firmicutes_A, as well as Bacteroides, 143

Bacteroides_B and Prevotella in phylum Bacteroidota were most abundant in a majority of 144 samples (Fig 1B) . 145

Baseline alpha-diversity measures significantly differed between incident asthma cases and 146 non-cases (P<0.01), with lower values of Shannon's, Chao1, and Pielou's indices in 147

individuals who went on to develop asthma (Fig 1C) . Alpha-diversity indices were not 148 significantly different between COPD cases and non-cases. Principal component analysis of 149

the centered log-ratio (CLR) transformed abundances showed no clear separation between 150 incident cases and non-cases (Fig 1D) , suggesting that the association of incident asthma 151

and COPD with the gut microbiome was unlikely related to the whole microbial community 152 and may be attributable to specific microbial taxa. 153

We assessed the association between baseline taxon-level microbial abundances and 154 incident respiratory diseases using Cox regression, based on centered log-ratios (Methods).

At 5% false discovery rate, significant associations of incident asthma were found in 5 phyla, 156 5 classes, 18 orders, 111 families, 257 genera and 299 species (Table S1) ; for incident COPD, 157

we found significant associations with 5 phyla, 7 classes, 32 orders, 57 families, 133 genera 158

and 158 species (Table S2) . Of the asthma-and COPD-associated taxa, 76% and 68.6% 159 showed positive associations with disease incidence, respectively. A number of highly 160 abundant genera were associated with incident asthma, such as Bacteroides, 161

Faecalibacterium, Agathobacter, Blautia_A and Roseburia (Fig 1E) . Among the most 162 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To investigate whether the baseline gut microbiome was predictive of incident asthma and 168 COPD, we train and validate prediction models via the machine learning algorithm of gradient 169

boosting decision trees. These models were trained with 5-fold cross-validation in 70% of the 170 individuals and then the performances were validated in the remaining 30% (Methods); all 171 performance metrics given are based on the 30% validation set unless otherwise specified. 172

Models were developed at different taxonomic levels separately and for a combination of all 173 taxonomic levels (Fig S1) . To assess sampling variation, we resampled training and testing 174

partitions at different taxonomic levels 10 times and report mean values of prediction 175

performance. 176

The best performance was obtained at individual taxonomic levels, rather than their 177 combination, for both asthma and COPD prediction. Generally better prediction performance 178 was attained at lower taxonomic levels, particularly for COPD where the highest average area 179 under the operating characteristic curve (AUC) was at species level (mean AUC = 0.780), 180

followed by genus (mean AUC = 0.734) and family (mean AUC = 0.688) levels. For prediction 181 of incident asthma, the best performance was obtained at family level (mean AUC = 0.608), 182

with slight attenuation of AUC scores obtained at genus (mean AUC = 0.592) and species 183

(mean AUC = 0.593) levels. 184

The gut microbiome had greater predictive value than individual conventional risk 185 factors 186

To compare the predictive value of conventional risk factors and the gut microbiome for 187 incident asthma and COPD, we first conducted univariate analysis using Cox models. We 188 utilised the optimal cross-validated gradient boosting model at family and species level for 189 asthma and COPD, respectively, and refer to the resultant score as a "gut microbiome score" 190 for each condition. We found that the gut microbiome score had a relatively high predictive 191 capacity with C-indices of 0.623 for asthma and 0.817 for COPD, which were each greater 192 than those of other risk factors (Fig 2) . there were no significant associations for baseline age and BMI ( Table 2) . For COPD, baseline 205 age, current smoking status and gut microbiome score were significant predictors (HR= 1.1 206 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 1.29], P<0.001 respectively). While consistent with the individual predictive power of the gut 208 microbiome score (Fig 2) , the multivariable Cox model showed the risk associated with current 209 smokers at baseline was significantly greater than other risk factors for COPD. 210

In subgroup analyses, the gut microbiome score association patterns were generally 211 consistent with those above (Fig 3) . For COPD, where current smoking status had a relatively 212 large hazard ratio, the gut microbiome score was independently associated with incident 213 COPD in both current smokers and non-smokers. In individuals who indicated past smoking 214

but who were not current smokers at survey (n=414), we found that the gut microbiome score 215

was not significantly associated with incident COPD (HR=1. statistical interactions of the gut microbiome score with age and sex (Fig 3) . 219

The integrated models showed significantly improved predictive capacity for both incident 220 asthma and COPD (Fig 4) . For asthma, a reference model of age, sex and BMI yielded C-221

index of 0.567; addition of smoking status then gut microbiome score increased the C-index 222 further to 0.626 and 0.656, respectively. For COPD, the reference model of age, sex and BMI 223

yielded C-index of 0.735; addition of smoking status then gut microbiome score increased the 224 C-index further to 0.855 and 0.862, respectively. 225

In this prospective study, we investigated the association and predictive capacity of the gut 227 microbiome for future chronic respiratory diseases, asthma and COPD, in adults using 228

shotgun metagenomics. We demonstrated that the gut microbiome is significantly associated 229

with incident asthma and COPD and evaluated the relative contributions of traditional risk 230

factors and a gut microbiome score. We then constructed integrated risk models which 231 maximised predictive performance. Taken together, our findings indicate that the gut 232 microbiome is a valid and potentially substantive biomarker for both asthma and COPD. 233

The gut and lung microbial communities, although residing in distal sites, are dominated by 234

broadly is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Clostridium, Veillonella, and B. fragilis were associated with increased incidence of asthma in 254 adulthood, consistent with that observed for childhood asthma [22, 43, 44] . In contrast to 255 previous findings showing that the relative abundances of Faecalibacterium, Roseburia and 256

Flavonifractor were decreased in childhood asthma [22, 43] , we found positive associations 257

with adult-onset asthma. We confirmed previous findings that increased abundances of 258

Clostridium and Eggerthella lenta in the adult gut microbiome were associated with 259

asthma [27] . The relationship between the gut microbiome and COPD is even less understood.

A recent study reported that Streptococcus sp000187445 was enriched in COPD patients and 261

was correlated with reduced lung function [30] , which was also confirmed by a positive 262 association with incident COPD in our study. 263

Regarding consideration of causality in observational studies, it is challenging to determine 264

whether the composition of the gut microbiome is a cause or consequence of respiratory 265

disease. In this respect, one strength of our study was the use of baseline gut microbiome and 266 incident disease systematically identified through EHRs. The follow-up using EHRs was nearly 267 complete in all samples (except for the small number of participants who moved abroad 268 permanently). Using machine learning models, we found that the baseline gut microbiome had 269 moderate predictive capacities in distinguishing incident cases from non-cases for asthma and 270 COPD, suggesting that there are detectable changes in the gut microbiome antecedent to the 271 onset of symptomatic disease. This does not confirm causality or eliminate other possibilities.

For example, disease-associated host changes and gut microbial alteration may influence 273 each other and operate simultaneously [40] . We also showed that the association between gut 274 microbiome-based predictions and incident asthma or COPD was largely independent of age, 275 sex, BMI and smoking, all of which can influence susceptibility to respiratory diseases [45] [46] [47] [48] .

Moreover, significant interactions of gut microbiome by sex and age were found, suggesting 277 different impact of gut microbiome on age and sex groups, consistent with findings in other 278 settings [49] [50] [51] . 279 Importantly, our study affirms the large body of evidence that smoking is associated with 280 respiratory illness, especially COPD. Despite many ways to characterise the smoking 281 phenotype, we found that individuals who reported being current smokers were at high risk of 282 future asthma and COPD. The association between smoking and gut microbiota is well 283 established and smoking cessation has been shown to have profound, putatively causal 284 effects on the gut microbiome[52]. Our results show that, particularly for COPD, the gut 285 microbiome is both a substantial independent predictor of future disease and that its predictive 286 power is partially explained by smoking behaviour. As such, our findings are both consistent 287

with previous studies and take us a step closer to delineating which and to what extent 288 particular gut microbial taxa sit along the causal path from smoking behaviour to future asthma 289 and COPD. For the latter, larger prospective studies will be necessary but population-scale 290 gut microbiome and e-health studies are under way. 291

There are limitations of the present study. Firstly, despite a relatively large sample size, our 292 study was enrolled from a single European country (Finland), and the generalizability of the 293 findings to other geographically-and culturally-distinct settings will require further 294 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint individual, which did not allow for dynamic or temporal assessment of gut microbiome 296 alterations along with incident disease onset. Changes in diet and environmental exposures 297

(apart from smoking) can induce changes in gut microbiota and should be considered in future 298 studies. While the asthma and COPD phenotypes can be difficult to diagnosis or indeed 299 overlap in some individuals, our study takes a pragmatic approach and future clinical cohorts 300 may be necessary to precisely quantify disease specific effects. Finally, although formal lung 301 function test results (FEV1, FVC) may further improve prediction, it was not feasible to perform 302

wholescale clinical examination of airflow obstruction at the population level. Regardless, our 303 study demonstrates that future exploration of the influence of the gut microbiome in severity 304

and progression of asthma and COPD is warranted, and may lead to further clinically-305 significant findings. 306

Our study supports the role of gut microbiome in adult respiratory disease and as potential 307

biomarkers that might aid in risk profiling of asthma and COPD. The underlying mechanisms 308 and causal links by which gut microbiota influence the lung, and vice versa, remain to be 309 established. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint genus and species levels were computed. The present analyses focused on common taxa 352 with relative abundances greater than 0.01% in more than 1% of samples. Three measures 353 of microbial diversity were calculated: Shannon's alpha diversity, Chao1 richness and Pielou's 354 evenness (R packages vegan and otuSummary). The centered log-ratio (CLR) transformation 355 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 was performed on abundance data, of which the zeros were substituted with 1/10 of non-zero 356 minimum abundance. Further analyses were based on CLR transformed abundances. 357

A machine learning framework was employed to develop prediction models at different 359 taxonomic levels separately. The samples were randomly partitioned into two subsets: (1) a 360

training dataset (70% of samples) for developing models, and (2) a validation dataset (30% of 361 samples) for evaluating prediction performance. We resampled the data 10 times and 362

performed the same training and validation procedure for each sampling partition. In each 363

training dataset, we first selected microbial indicators for predicting incident asthma and 364 COPD; we analyzed the relationships between taxon-level abundance and incident disease 365 using logistic regression adjusted for age and sex, Cox regression for time to disease onset 366 adjusted for age and sex and Spearman correlation. The taxa that were associated with 367 incident diseases at a significance threshold of P<0.05 by any of the above approaches were 368

selected for further analyses. The selected taxa together with diversity measurements were 369 considered as microbial predictors for developing prediction models. Next, gradient boosting 370 decision tree (implemented by Xgboost) models were developed with Bayesian optimization 371

through 5-fold cross-validation to determine optimal hyperparameters. The optimal setting was 372 then trained on the whole training data to build the final model used in validation. We 373 additionally performed ridge logistic regression to compare the prediction performance using 374 the same samples for training and testing. The gradient boosted trees-based models 375

outperformed those based on ridge logistic regression. A similar trend of prediction 376 performance across taxonomic levels was observed with both methods. The final performance 377 across various models and partitions was assessed in the validation datasets. 378

Wilcoxon rank-sum test was performed to compare differences in patient characteristics, gut 379 microbial relative abundances and diversity metrics between incident cases and non-cases. 380

Cox regression with adjustment of age and sex was utilized to assess the association between 381 taxon-level CLR abundance and incident disease using all samples (FDR<0.05 was 382 considered as statistical significance). The gut microbiome-based predictions from the optimal 383 gradient boosting model were used as the gut microbiome scores for further analyses in its 384 respective validation dataset for each disease condition. Cox models of conventional risk 385 factors and in combination with the gut microbiome score were built using the time from 386

baseline to the occurrence of the disease or end of follow-up. Machine learning and statistical 387 analysis of data were carried out in R (version 3.6.1). 388 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 23, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Global Initiative for the Diagnosis, Management, and Prevention of 463 Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 464 and Chronic Obstructive Pulmonary Disease

Therapeutic approaches to asthma-chronic obstructive pulmonary disease 469 overlap syndromes

Chronic Obstructive Pulmonary Disease Phenotypes: Implications for 471 Care

Understanding Asthma Phenotypes, Endotypes, and 473 Mechanisms of Disease

Diagnosis and Management of Asthma in Adults: A Review

The Challenge of Controlling the COPD Epidemic

Diagnosis and Outpatient Management of Chronic Obstructive 479 Pulmonary Disease: A Review

Functional effects of the microbiota in chronic respiratory disease

Microbiomes in respiratory health and disease: An Asia-Pacific 483 perspective

The gut microbiome in health and in disease

The respiratory tract microbiome and lung 487 inflammation: a two-way street

The microbiome in the lower respiratory tract

Lung microbiome dynamics in COPD exacerbations

The airway microbiome in patients with severe asthma: Associations with 493 disease features and severity

Airway microbiome dynamics in exacerbations of chronic obstructive 495 pulmonary disease

The infant nasopharyngeal microbiome impacts severity of lower respiratory 497 infection and risk of asthma development

Airway Microbiota Dynamics Uncover a Critical Window for Interplay of 499

Pathogenic Bacteria and Allergy in Childhood Respiratory Disease

Microbes, metabolites, and the gut-lung axis. Mucosal 502 Immunol

The Role of Lung and Gut Microbiota in the Pathology of Asthma

Maturation of the gut microbiome and risk of asthma in childhood

Maturation of the gut microbiome during the first year of life contributes to 508 the protective farm effect on childhood asthma

The microbiome in asthma

The microbiome in early life: implications for health outcomes

Histamine-secreting microbes are increased in the gut of adult asthma 514 patients

A metagenome-wide association study of gut microbiota in asthma in UK 516 adults

Gut microbiota relationships to lung function and adult asthma phenotype: a 518 pilot study

Allergic Patients with Long-Term Asthma Display Low Levels of 520 Bifidobacterium adolescentis

Disease-associated gut microbiome and metabolome changes in 522 patients with chronic obstructive pulmonary disease

Taxonomic signatures of cause-specific mortality risk in human gut 524 microbiome

Cohort Profile: The National FINRISK Study

A standardized bacterial taxonomy based on genome phylogeny 528 substantially revises the tree of life

Dysbiosis of the gut and lung microbiome has a role in asthma

The Lung Microbiome, Immunity, and the 532 Pathogenesis of Chronic Lung Disease

Bronchial microbiome of severe COPD patients colonised by Pseudomonas 534 aeruginosa

Pseudomonas aeruginosa in patients hospitalised for COPD 536 exacerbation: a prospective study

Impact of Pseudomonas aeruginosa Infection on Patients with 538 Chronic Inflammatory Airway Diseases

The effect of Pseudomonas aeruginosa on pulmonary function in patients 540 with bronchiectasis

Emerging pathogenic links between microbiota and the gut-lung axis. Nat 542 Rev Microbiol

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung 544 Diseases. Front Microbiol

Early infancy microbial and metabolic alterations affect risk of childhood 546 asthma

Gut microbial-derived butyrate is inversely associated with IgE responses to 548 allergens in childhood asthma

Early intestinal Bacteroides fragilis colonisation and development of asthma

Gender and chronic obstructive pulmonary disease: why it matters. Am J 552 Respir Crit Care Med

Obesity and respiratory diseases

Smoking, asthma, chronic airflow obstruction and COPD

Gut microbiota and aging

Intestinal Microbiota Is Influenced by Gender and Body Mass Index. PLoS 561 One

The Impact of Gut Microbiota on Gender-Specific Differences in Immunity. 563 Front Immunol

Smoking cessation induces profound changes in the composition of the 565 intestinal microbiota in humans

The validity of the Finnish Hospital Discharge Register and Causes of Death 567 Register data on coronary heart disease

The validation of the Finnish Hospital Discharge Register and Causes of 570

Death Register data on stroke diagnoses

Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J 573 Public Health

Evaluating the Information Content of Shallow Shotgun Metagenomics. 575 mSystems

Snakemake--a scalable bioinformatics workflow engine

Centrifuge: rapid and sensitive classification of metagenomic sequences